文献速递前列腺癌

基于端粒的风险模型用于临床显著性前列腺癌的早期诊断

Telomere-based risk models for the early diagnosis of clinically significant prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-05-04

本研究在401例PSA 3-10 ng/ml且未活检的患者中,评估端粒相关变量(TAV)作为补充生物标志物区分非显著与显著前列腺癌(Gleason评分>6)的价值。通过主成分分析和随机森林构建两个TAV风险模型,在全队列中AUC≥0.83,内部验证队列AUC>0.76,且在低风险概率区间决策能力优于PCPT-RC。验证队列中模型1和2分别可避免33%和48%的活检,漏诊显著癌比例分别为0和10.3%。

要点

  • TAV风险模型在全队列AUC≥0.83,内部验证AUC>0.76
  • 验证队列中模型1可避免33%活检且不漏诊显著癌
  • 模型在低风险概率区间决策能力优于PCPT-RC

核心结论

  • 端粒分析(TAV)可作为新的风险评分生物标志物,有望提升PSA 3-10 ng/ml患者显著前列腺癌的预测能力。

研究设计与样本

  • 前瞻性纵向研究亚组,纳入401例PSA 3-10 ng/ml且无既往活检的可疑前列腺癌患者。
  • 队列随机分为训练集(2/3)和验证集(1/3),另在独立回顾性非同期队列中测试验证。
  • 采用高通量定量荧光原位杂交评估外周血单核细胞中的TAV,通过主成分分析和随机森林构建模型。

主要发现

  • 患者中位年龄63岁,中位PSA 5 ng/ml,前列腺癌诊断率40.6%,显著前列腺癌19.2%。
  • 两个TAV风险模型在全研究队列中AUC≥0.83,内部验证队列AUC>0.76。
  • 验证队列中,模型1和2分别可避免33%和48%的活检,漏诊显著前列腺癌比例分别为0和10.3%。
  • 两个模型在低风险概率区间决策能力优于PCPT-RC。

关键数值与推荐

  • 显著前列腺癌定义为Gleason评分>6。
  • TAV模型1和2在全队列AUC≥0.83,内部验证AUC>0.76。
  • 验证队列中模型1避免33%活检,漏诊0%显著癌;模型2避免48%活检,漏诊10.3%显著癌。

临床怎么用

  • 对于PSA 3-10 ng/ml且未活检的患者,可考虑结合TAV风险模型辅助判断是否需前列腺穿刺。
  • TAV模型在低风险概率区间可能优于PCPT-RC,有助于减少不必要活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objective of this study was to explore telomere-associated variables (TAV) as complementary biomarkers in the early diagnosis of prostate cancer (PCa), analyzing their application in risk models for significant PCa (Gleason score > 6). METHODS: As part of a larger prospective longitudinal study of patients with suspicion of PCa undergoing prostate biopsy according to clinical practice, a subgroup of patients (n = 401) with PSA 3-10 ng/ml and no prior biopsies was used to evaluate the contribution of TAV to discern non-significant PCa from significant PCa. The cohort was randomly split for training (2/3) and validation (1/3) of the models. High-throughput quantitative fluorescence in-situ hybridization was used to evaluate TAV in peripheral blood mononucleated cells. Models were generated following principal component analysis and random forest and their utility as risk predictors was evaluated by analyzing their predictive capacity and accuracy, summarized by ROC curves, and their clinical benefit with decision curves analysis. RESULTS: The median age of the patients was 63 years, with a median PSA of 5 ng/ml and a percentage of PCa diagnosis of 40.6% and significant PCa of 19.2%. Two TAV-based risk models were selected (TAV models 1 and 2) with an AUC ≥ 0.83 in the full study cohort, and AUC > 0.76 in the internal validation cohort. Both models showed an improvement in decision capacity when compared to the application of the PCPT-RC in the low-risk probabilities range. In the validation cohort, with TAV models 1 and 2, 33% /48% of biopsies would have been avoided losing 0/10.3% of significant PCa, respectively. The models were also tested and validated on an independent, retrospective, non contemporary cohort. CONCLUSIONS: Telomere analysis through TAV should be considered as a new risk-score biomarker with potential to increase the prediction capacity of significant PCa in patients with PSA between 3-10 ng/ml.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Rubio Galisteo JM, Fernández L, Gómez Gómez E, et al. Telomere-based risk models for the early diagnosis of clinically significant prostate cancer. Prostate Cancer Prostatic Dis. 2020. PMID: 32367011. doi:10.1038/s41391-020-0232-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。